ENTA - Enanta Pharmaceuticals Stock Price, News & Analysis

$47.68 2.03 (4.45 %)
(As of 11/24/2017 03:25 PM ET)
Previous Close$45.65
Today's Range$45.14 - $47.94
52-Week Range$25.92 - $50.92
Volume225,800 shs
Average Volume195,619 shs
Market Capitalization$910.23 million
P/E Ratio54.18
Dividend YieldN/A
Beta0.66

About Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals logoEnanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.


Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ENTA
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio11.34%
Quick Ratio18.54%

Price-To-Earnings

Trailing P/E Ratio54.18
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$102.81 million
Price / Sales8.85
Cash Flow$1.30 per share
Price / Cash36.54
Book Value$15.80 per share
Price / Book3.02

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS$0.88
Net Income$21.66 million
Net Margins17.23%
Return on Equity6.46%
Return on Assets6.11%

Miscellaneous

Employees76
Outstanding Shares19,090,000

Frequently Asked Questions for Enanta Pharmaceuticals (NASDAQ:ENTA)

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced its earnings results on Monday, November, 20th. The biotechnology company reported $1.86 EPS for the quarter, missing the Zacks' consensus estimate of $2.13 by $0.27. The biotechnology company had revenue of $75.93 million for the quarter, compared to the consensus estimate of $73.80 million. Enanta Pharmaceuticals had a net margin of 17.23% and a return on equity of 6.46%. The business's quarterly revenue was up 491.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.09) EPS. View Enanta Pharmaceuticals' Earnings History.

When will Enanta Pharmaceuticals make its next earnings announcement?

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 6th 2018. View Earnings Estimates for Enanta Pharmaceuticals.

Where is Enanta Pharmaceuticals' stock going? Where will Enanta Pharmaceuticals' stock price be in 2017?

4 brokerages have issued 12 month target prices for Enanta Pharmaceuticals' shares. Their forecasts range from $36.00 to $58.00. On average, they expect Enanta Pharmaceuticals' share price to reach $46.25 in the next twelve months. View Analyst Ratings for Enanta Pharmaceuticals.

Who are some of Enanta Pharmaceuticals' key competitors?

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the folowing people:

  • Bruce L.A. Carter Ph.D., Chairman of the Board,Independent Director (Age 73)
  • Jay R. Luly Ph.D., President, Chief Executive Officer, Director (Age 60)
  • Paul J. Mellett Jr., Chief Financial Officer, Senior Vice President - Finance & Administration (Age 61)
  • Yat Sun Sun Or Ph.D., Senior Vice President - Research & Development, Chief Scientific Officer (Age 64)
  • Nathaniel S. Gardiner J.D., Senior Vice President, General Counsel (Age 63)
  • Nathalie Adda M.D., Senior Vice President and Chief Medical Officer (Age 51)
  • Timothy D. Ocain Ph.D., Senior Vice President - New Product Strategy and Development (Age 59)
  • Kristine Peterson, Director (Age 57)
  • Ernst-Gunter Afting M.D., Ph.D.,, Independent Director (Age 74)
  • Stephen Buckley Jr., Independent Director (Age 67)

Who owns Enanta Pharmaceuticals stock?

Enanta Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include First Manhattan Co. (4.96%), Dimensional Fund Advisors LP (2.95%), Stonepine Capital Management LLC (2.04%), Candriam Luxembourg S.C.A. (1.18%), Bank of New York Mellon Corp (0.94%) and Ameriprise Financial Inc. (0.75%). Company insiders that own Enanta Pharmaceuticals stock include Nathaniel S Gardiner, Paul J Mellett, Terry Vance and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

Who sold Enanta Pharmaceuticals stock? Who is selling Enanta Pharmaceuticals stock?

Enanta Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Candriam Luxembourg S.C.A., Granahan Investment Management Inc. MA, JPMorgan Chase & Co., Virginia Retirement Systems ET AL, Bank of New York Mellon Corp, AlphaMark Advisors LLC and Strs Ohio. View Insider Buying and Selling for Enanta Pharmaceuticals.

Who bought Enanta Pharmaceuticals stock? Who is buying Enanta Pharmaceuticals stock?

Enanta Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., First Manhattan Co., New York State Common Retirement Fund, GSA Capital Partners LLP, Dimensional Fund Advisors LP, Crossmark Global Holdings Inc., Hartland & Co. LLC and Wells Fargo & Company MN. Company insiders that have bought Enanta Pharmaceuticals stock in the last two years include Nathaniel S Gardiner and Terry Vance. View Insider Buying and Selling for Enanta Pharmaceuticals.

How do I buy Enanta Pharmaceuticals stock?

Shares of Enanta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enanta Pharmaceuticals' stock price today?

One share of Enanta Pharmaceuticals stock can currently be purchased for approximately $47.68.

How big of a company is Enanta Pharmaceuticals?

Enanta Pharmaceuticals has a market capitalization of $910.23 million and generates $102.81 million in revenue each year. The biotechnology company earns $21.66 million in net income (profit) each year or $0.88 on an earnings per share basis. Enanta Pharmaceuticals employs 76 workers across the globe.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]


MarketBeat Community Rating for Enanta Pharmaceuticals (ENTA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  128 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  282
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $46.25 (3.00% downside)

Consensus Price Target History for Enanta Pharmaceuticals (NASDAQ:ENTA)

Price Target History for Enanta Pharmaceuticals (NASDAQ:ENTA)

Analysts' Ratings History for Enanta Pharmaceuticals (NASDAQ:ENTA)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017Royal Bank Of CanadaBoost Price TargetOutperform -> Outperform$54.00 -> $58.00N/AView Rating Details
10/4/2017JMP SecuritiesBoost Price Target$40.00 -> $53.00LowView Rating Details
8/9/2017J P Morgan Chase & CoReiterated RatingOverweight$32.00 -> $38.00LowView Rating Details
8/8/2017Robert W. BairdBoost Price TargetNeutral$27.00 -> $36.00MediumView Rating Details
2/9/2016Barclays PLCBoost Price TargetUnderweight$16.00 -> $18.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Enanta Pharmaceuticals (NASDAQ:ENTA)

Earnings by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Earnings History by Quarter for Enanta Pharmaceuticals (NASDAQ ENTA)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/6/2018$0.17N/AView Earnings Details
11/20/2017Q4 2017$2.13$1.86$73.80 million$75.93 millionViewN/AView Earnings Details
8/7/2017Q3 2017($0.49)($0.44)$8.08 million$7.51 millionViewListenView Earnings Details
5/8/2017Q2 2017($0.38)($0.28)$9.19 million$9.00 millionViewListenView Earnings Details
2/8/2017Q117($0.18)($0.26)$12.70 million$11.90 millionViewListenView Earnings Details
11/21/2016Q416($0.11)($0.09)$13.56 million$12.80 millionViewListenView Earnings Details
8/8/2016Q216($0.09)($0.06)$13.07 million$14.00 millionViewListenView Earnings Details
5/9/2016Q2$0.10($0.09)$16.80 million$13.00 millionViewListenView Earnings Details
2/8/2016Q116$1.13$1.36$47.32 million$48.40 millionViewListenView Earnings Details
11/23/2015Q415$0.15$0.29$16.44 million$14.40 millionViewListenView Earnings Details
8/6/2015Q315$0.19$0.13$16.18 million$11.60 millionViewListenView Earnings Details
5/7/2015Q215$1.80$1.49$63.40 million$57.40 millionViewListenView Earnings Details
2/5/2015Q115$3.82$2.18$86.62 million$77.50 millionViewN/AView Earnings Details
11/24/2014Q414($0.33)($0.27)$3.81 million$2.60 millionViewListenView Earnings Details
8/11/2014Q314$1.65$1.81$40.83 million$42.10 millionViewN/AView Earnings Details
5/12/2014Q2$0.69($0.28)$1.20 million$2.20 millionViewListenView Earnings Details
2/13/2014Q114($0.15)($0.30)$1.41 million$0.89 millionViewN/AView Earnings Details
11/25/2013Q4($0.29)($0.25)$1.00 million$1.30 millionViewListenView Earnings Details
8/12/2013Q213($0.34)($0.23)$0.73 million$1.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)
Current Year EPS Consensus Estimate: $-1.57 EPS

Dividends

Dividend History for Enanta Pharmaceuticals (NASDAQ:ENTA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Enanta Pharmaceuticals (NASDAQ ENTA)

Insider Ownership Percentage: 9.28%
Institutional Ownership Percentage: 66.45%
Insider Trades by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)
Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Insider Trades by Quarter for Enanta Pharmaceuticals (NASDAQ ENTA)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/4/2017Yat Sun OrInsiderSell13,921$35.09$488,487.89View SEC Filing  
11/29/2016Yat Sun OrInsiderSell13,921$31.44$437,676.24View SEC Filing  
5/11/2016Nathaniel S GardinerVPBuy500$24.45$12,225.00View SEC Filing  
2/12/2016Terry VanceDirectorBuy2,000$27.04$54,080.00View SEC Filing  
11/24/2015Paul J. MellettCFOSell6,000$30.15$180,900.00View SEC Filing  
10/15/2015Paul J MellettCFOSell7,500$40.10$300,750.00View SEC Filing  
9/8/2015Paul J. MellettCFOSell7,500$39.55$296,625.00View SEC Filing  
7/13/2015Paul J MellettCFOSell7,500$46.29$347,175.00View SEC Filing  
7/13/2015Yat Sun OrInsiderSell3,750$46.29$173,587.50View SEC Filing  
6/11/2015Paul J MellettCFOSell7,500$42.51$318,825.00View SEC Filing  
6/11/2015Yat Sun OrInsiderSell3,750$42.47$159,262.50View SEC Filing  
6/5/2015Yat Sun OrInsiderSell10,750$42.02$451,715.00View SEC Filing  
5/19/2015Paul J MellettCFOSell24,000$40.13$963,120.00View SEC Filing  
5/11/2015Yat Sun OrInsiderSell8,000$36.13$289,040.00View SEC Filing  
3/9/2015Jay R LulyCEOSell15,000$33.37$500,550.00View SEC Filing  
2/20/2015Jay R LulyCEOSell15,000$35.35$530,250.00View SEC Filing  
2/19/2015Stephen Jr. BuckleyDirectorBuy1,000$34.00$34,000.00View SEC Filing  
2/17/2015Nathaniel S GardinerVPBuy1,400$33.23$46,522.00View SEC Filing  
1/16/2015Paul J MellettCFOSell4,500$49.45$222,525.00View SEC Filing  
1/5/2015Jay R LulyCEOSell15,000$50.43$756,450.00View SEC Filing  
12/1/2014Jay R LulyCEOSell15,000$45.39$680,850.00View SEC Filing  
11/3/2014Jay R LulyCEOSell15,000$42.52$637,800.00View SEC Filing  
9/15/2014Paul J MellettCFOSell10,000$39.83$398,300.00View SEC Filing  
8/14/2014Paul J MellettCFOSell10,000$39.13$391,300.00View SEC Filing  
8/14/2014Stephen Jr. BuckleyDirectorBuy1,000$38.95$38,950.00View SEC Filing  
7/14/2014Paul J MellettCFOSell20,000$39.88$797,600.00View SEC Filing  
5/1/2014Yat Sun OrInsiderSell5,000$36.98$184,900.00View SEC Filing  
4/1/2014Jay LulyCEOSell15,000$39.17$587,550.00View SEC Filing  
4/1/2014Yat Sun OrInsiderSell10,000$39.16$391,600.00View SEC Filing  
3/24/2014Yat Sun OrInsiderSell10,000$39.34$393,400.00View SEC Filing  
3/4/2014V Life Science Ventures Gm Tvmmajor shareholderSell439,334$38.82$17,054,945.88View SEC Filing  
2/26/2014V Life Science Ventures Gm Tvmmajor shareholderSell230,190$39.15$9,011,938.50View SEC Filing  
2/24/2014V Life Science Ventures Gm Tvmmajor shareholderSell60,477$39.57$2,393,074.89View SEC Filing  
2/14/2014Jay LulyCEOSell5,800$38.10$220,980.00View SEC Filing  
1/2/2014Jay R LulyCEOSell5,800$28.05$162,690.00View SEC Filing  
12/6/2013Marc E GoldbergDirectorSell6,861$27.93$191,627.73View SEC Filing  
10/14/2013Saints Capital Granite, L.P.Major ShareholderSell32,301$19.84$640,851.84View SEC Filing  
10/10/2013Saints Capital Granite, L.P.Major ShareholderSell36,207$21.71$786,053.97View SEC Filing  
10/3/2013Saints Capital Granite, L.P.Major ShareholderSell12,300$23.39$287,697.00View SEC Filing  
3/26/2013Helmut SchuhslerDirectorBuy132,949$14.00$1,861,286.00View SEC Filing  
3/26/2013Saints Capital Granite, L.P.Major ShareholderBuy66,474$14.00$930,636.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Enanta Pharmaceuticals (NASDAQ ENTA)

Source:
DateHeadline
Enanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ENTA-US : November 22, 2017Enanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ENTA-US : November 22, 2017
finance.yahoo.com - November 22 at 3:33 PM
Enanta Pharmaceuticals, Inc. to Host Earnings CallEnanta Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 21 at 6:31 PM
ETFs with exposure to Enanta Pharmaceuticals, Inc. : November 21, 2017ETFs with exposure to Enanta Pharmaceuticals, Inc. : November 21, 2017
finance.yahoo.com - November 21 at 6:31 PM
Enanta Pharmaceuticals, Inc. (ENTA) Announces Quarterly  Earnings ResultsEnanta Pharmaceuticals, Inc. (ENTA) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 21 at 7:43 AM
Royal Bank Of Canada Boosts Enanta Pharmaceuticals, Inc. (ENTA) Price Target to $58.00Royal Bank Of Canada Boosts Enanta Pharmaceuticals, Inc. (ENTA) Price Target to $58.00
www.americanbankingnews.com - November 21 at 7:43 AM
Short Interest In Enanta Pharmaceuticals Moves 22.6% LowerShort Interest In Enanta Pharmaceuticals Moves 22.6% Lower
www.thestreet.com - November 21 at 5:09 AM
Edited Transcript of ENTA earnings conference call or presentation 20-Nov-17 9:30pm GMTEdited Transcript of ENTA earnings conference call or presentation 20-Nov-17 9:30pm GMT
finance.yahoo.com - November 21 at 5:09 AM
Enanta Pharmaceuticals posts 4Q profitEnanta Pharmaceuticals posts 4Q profit
finance.yahoo.com - November 20 at 7:06 PM
Enanta Pharmaceuticals, Inc. (ENTA) Given Average Recommendation of "Buy" by BrokeragesEnanta Pharmaceuticals, Inc. (ENTA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 13 at 12:34 PM
Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2017Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2017
finance.yahoo.com - November 13 at 11:33 AM
Enanta Pharmaceuticals, Inc. (ENTA) to Release Earnings on MondayEnanta Pharmaceuticals, Inc. (ENTA) to Release Earnings on Monday
www.americanbankingnews.com - November 13 at 2:08 AM
Enanta Pharmaceuticals Ranked As One Of North Americas Fastest Growing Companies On Deloittes 2017 Technology Fast 500™Enanta Pharmaceuticals Ranked As One Of North America's Fastest Growing Companies On Deloitte's 2017 Technology Fast 500™
www.thestreet.com - November 11 at 1:00 PM
Enanta Pharmaceuticals Ranked as One of North America’s Fastest Growing Companies on Deloitte’s 2017 Technology Fast 500™Enanta Pharmaceuticals Ranked as One of North America’s Fastest Growing Companies on Deloitte’s 2017 Technology Fast 500™
finance.yahoo.com - November 10 at 12:53 PM
Zacks: Brokerages Anticipate Enanta Pharmaceuticals, Inc. (ENTA) Will Announce Quarterly Sales of $72.75 MillionZacks: Brokerages Anticipate Enanta Pharmaceuticals, Inc. (ENTA) Will Announce Quarterly Sales of $72.75 Million
www.americanbankingnews.com - November 9 at 10:48 AM
ETFs with exposure to Enanta Pharmaceuticals, Inc. : November 8, 2017ETFs with exposure to Enanta Pharmaceuticals, Inc. : November 8, 2017
finance.yahoo.com - November 9 at 2:08 AM
Comparing Enanta Pharmaceuticals (ENTA) and Oncobiologics (ONS)Comparing Enanta Pharmaceuticals (ENTA) and Oncobiologics (ONS)
www.americanbankingnews.com - November 9 at 1:12 AM
Enanta Pharmaceuticals, Inc. (ENTA) Expected to Announce Earnings of $1.94 Per ShareEnanta Pharmaceuticals, Inc. (ENTA) Expected to Announce Earnings of $1.94 Per Share
www.americanbankingnews.com - November 7 at 10:16 AM
Enanta Pharma (ENTA) Reports Positive Phase 1 a/b Clinical Results for its Lead FXR Agonist, EDP-305Enanta Pharma (ENTA) Reports Positive Phase 1 a/b Clinical Results for its Lead FXR Agonist, EDP-305
www.streetinsider.com - October 25 at 3:12 AM
Enanta Pharmaceuticals Announces Positive Phase 1 a/b Clinical Results for its Lead FXR Agonist, EDP-305Enanta Pharmaceuticals Announces Positive Phase 1 a/b Clinical Results for its Lead FXR Agonist, EDP-305
finance.yahoo.com - October 23 at 3:59 PM
Enanta Pharma (ENTA) to Present New Preclinical Data on EDP-305, an FXR Agonist for NASH and PBC at AASLDEnanta Pharma (ENTA) to Present New Preclinical Data on EDP-305, an FXR Agonist for NASH and PBC at AASLD
www.streetinsider.com - October 21 at 5:36 PM
Enanta Pharmaceuticals, Inc. (ENTA) Given Buy Rating at Royal Bank Of CanadaEnanta Pharmaceuticals, Inc. (ENTA) Given Buy Rating at Royal Bank Of Canada
www.americanbankingnews.com - October 21 at 8:14 AM
Enanta Pharmaceuticals to Present New Preclinical Data on EDP-305, an FXR Agonist for NASH and PBC, at The Liver Meeting® 2017Enanta Pharmaceuticals to Present New Preclinical Data on EDP-305, an FXR Agonist for NASH and PBC, at The Liver Meeting® 2017
finance.yahoo.com - October 20 at 3:50 PM
Enanta Pharmaceuticals, Inc. (ENTA) Expected to Post Quarterly Sales of $72.75 MillionEnanta Pharmaceuticals, Inc. (ENTA) Expected to Post Quarterly Sales of $72.75 Million
www.americanbankingnews.com - October 20 at 3:34 AM
Enanta Pharmaceuticals, Inc. (ENTA) Given Consensus Rating of "Buy" by BrokeragesEnanta Pharmaceuticals, Inc. (ENTA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 19 at 12:54 PM
Edited Transcript of ENTA earnings conference call or presentation 8-May-17 8:30pm GMTEdited Transcript of ENTA earnings conference call or presentation 8-May-17 8:30pm GMT
finance.yahoo.com - October 17 at 7:06 PM
Is There Now An Opportunity In Enanta Pharmaceuticals Inc (ENTA)?Is There Now An Opportunity In Enanta Pharmaceuticals Inc (ENTA)?
finance.yahoo.com - October 12 at 7:09 PM
Enanta Announces Data to be Presented on AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) at The Liver Meeting® 2017Enanta Announces Data to be Presented on AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) at The Liver Meeting® 2017
finance.yahoo.com - October 11 at 7:53 PM
Enanta Pharmaceuticals, Inc. (ENTA) Raised to "Hold" at Zacks Investment ResearchEnanta Pharmaceuticals, Inc. (ENTA) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 10 at 7:40 PM
Enanta Pharmaceuticals (ENTA) versus Its Rivals Critical ComparisonEnanta Pharmaceuticals (ENTA) versus Its Rivals Critical Comparison
www.americanbankingnews.com - October 9 at 8:10 AM
Enanta Pharmaceuticals, Inc. (ENTA) PT Raised to $53.00 at JMP SecuritiesEnanta Pharmaceuticals, Inc. (ENTA) PT Raised to $53.00 at JMP Securities
www.americanbankingnews.com - October 8 at 6:40 PM
ETFs with exposure to Enanta Pharmaceuticals, Inc. : October 4, 2017ETFs with exposure to Enanta Pharmaceuticals, Inc. : October 4, 2017
finance.yahoo.com - October 4 at 5:05 PM
Enanta Pharma (ENTA) Presents At Cantor Fitzgerald Global Healthcare Conference - SlideshowEnanta Pharma (ENTA) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 29 at 2:52 PM
Enanta Announces that AbbVie’s MAVIRET™ (glecaprevir/pibrentasvir) Received Approval in Japan for the Treatment of All Major Genotypes (GT1-6) of Chronic Hepatitis CEnanta Announces that AbbVie’s MAVIRET™ (glecaprevir/pibrentasvir) Received Approval in Japan for the Treatment of All Major Genotypes (GT1-6) of Chronic Hepatitis C
www.businesswire.com - September 27 at 11:34 PM
Enanta Pharma (ENTA) Presents At Cambridge Healthtech Institutes 15th Annual Discovery On Target - SlideshowEnanta Pharma (ENTA) Presents At Cambridge Healthtech Institute's 15th Annual Discovery On Target - Slideshow
seekingalpha.com - September 27 at 11:34 PM
Reviewing Enanta Pharmaceuticals (ENTA) and The CompetitionReviewing Enanta Pharmaceuticals (ENTA) and The Competition
www.americanbankingnews.com - September 25 at 2:18 PM
Enanta Pharmaceuticals, Inc. (ENTA) Given Average Rating of "Buy" by BrokeragesEnanta Pharmaceuticals, Inc. (ENTA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 24 at 1:16 PM
ETFs with exposure to Enanta Pharmaceuticals, Inc. : September 19, 2017ETFs with exposure to Enanta Pharmaceuticals, Inc. : September 19, 2017
finance.yahoo.com - September 19 at 6:15 PM
Enanta Pharmaceuticals, Inc. :ENTA-US: Earnings Analysis: Q3, 2017 By the Numbers : September 18, 2017Enanta Pharmaceuticals, Inc. :ENTA-US: Earnings Analysis: Q3, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 18 at 6:09 PM
Enanta Pharmaceuticals, Inc. (ENTA) Coverage Initiated at Royal Bank Of CanadaEnanta Pharmaceuticals, Inc. (ENTA) Coverage Initiated at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 11:06 PM
Enanta Pharmaceuticals Announces the Appointment of Kristine Peterson to Its Board of DirectorsEnanta Pharmaceuticals Announces the Appointment of Kristine Peterson to Its Board of Directors
finance.yahoo.com - September 13 at 7:40 PM
Enanta Pharmaceuticals (ENTA) versus Global Blood Therapeutics (GBT) Head-To-Head AnalysisEnanta Pharmaceuticals (ENTA) versus Global Blood Therapeutics (GBT) Head-To-Head Analysis
www.americanbankingnews.com - September 8 at 12:30 PM
Nabriva Therapeutics AG (NBRV) vs. Enanta Pharmaceuticals (ENTA) Critical ContrastNabriva Therapeutics AG (NBRV) vs. Enanta Pharmaceuticals (ENTA) Critical Contrast
www.americanbankingnews.com - September 5 at 10:22 AM
Enanta Pharmaceuticals to Present at Three Upcoming Investor ConferencesEnanta Pharmaceuticals to Present at Three Upcoming Investor Conferences
finance.yahoo.com - August 30 at 7:35 PM
Enanta Pharmaceuticals (ENTA) Looks Good: Stock Adds 9.6% in SessionEnanta Pharmaceuticals (ENTA) Looks Good: Stock Adds 9.6% in Session
finance.yahoo.com - August 28 at 6:05 PM
$72.75 Million in Sales Expected for Enanta Pharmaceuticals, Inc. (ENTA) This Quarter$72.75 Million in Sales Expected for Enanta Pharmaceuticals, Inc. (ENTA) This Quarter
www.americanbankingnews.com - August 25 at 6:00 AM
Surging Earnings Estimates Signal Good News for Enanta Pharmaceuticals (ENTA)Surging Earnings Estimates Signal Good News for Enanta Pharmaceuticals (ENTA)
finance.yahoo.com - August 23 at 10:42 PM
Head-To-Head Survey: Enanta Pharmaceuticals (ENTA) versus Codexis (CDXS)Head-To-Head Survey: Enanta Pharmaceuticals (ENTA) versus Codexis (CDXS)
www.americanbankingnews.com - August 21 at 10:22 PM
J P Morgan Chase & Co Reiterates "Overweight" Rating for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)J P Morgan Chase & Co Reiterates "Overweight" Rating for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)
www.americanbankingnews.com - August 10 at 12:22 AM
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Releases Quarterly  Earnings Results, Beats Estimates By $0.05 EPSEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS
www.americanbankingnews.com - August 8 at 12:46 PM
Edited Transcript of ENTA earnings conference call or presentation 7-Aug-17 8:30pm GMTEdited Transcript of ENTA earnings conference call or presentation 7-Aug-17 8:30pm GMT
finance.yahoo.com - August 8 at 4:39 AM

Social Media

Financials

Chart

Enanta Pharmaceuticals (NASDAQ ENTA) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.